Akorn shareholders approve merger deal with Fresenius Kabi

Akorn Inc. (NSDQ:AKRX) shareholders voted yesterday to approve its $4.75 billion merger deal with German healthcare company Fresenius (ETR:FRE).

Fresenius’ Kabi division announced in April that it inked a deal to acquire the generic drugmaker, bringing with it a portfolio of ophthalmic drugs, ear drops, nasal sprays, respiratory drugs and medical creams.

Get the full story at our sister site, Drug Delivery Business News.

The post Akorn shareholders approve merger deal with Fresenius Kabi appeared first on MassDevice.

from MassDevice http://ift.tt/2tiSyTX